Table 3 Baseline data available from patients who were allocated to the study (intervention = 1034, control = 501)

Number of patients

770

359

172

97

92

45

Age (years)

64.6 (9.4)

65.6 (9.5)

65.4 (9.4)

66.0 (8.6)

67.3 (7.9)

62.4 (7.7)

Sex (% male)

58.3

54.0

69.2

73.2

65.2

64.4

Age at self reported year of diagnosis

54.3 (11.1)

56.1 (11.8)

60.8 (10.2)

61.3 (10.1)

63.9 (7.9)

56.8 (9.3)

311

145

121

69

51

25

Self-reported duration of disease

10.3 (8.4)

9.2 (8.2)

4.7 (6.6)

4.8 (7.6)

4.4 (5.4)

4.2 (3.7)

302

142

120

68

51

25

Body mass index

32.3 (6.2)

31.9 (5.7)

28.3 (4.1)

28.8 (5.1)

30.2 (6.6)

29.9 (6.9)

727

338

164

91

81

42

Waist circumference (M/F)

109.9 (14.4)/ 106.8 (15.5)

110.1 (12.8)/ 104.8 (15.1)

100.3 (11.0)/ 95.1 (12.8)

102.9 (11.7)/ 91.5 (12.6)

106.7 (12.8)/ 94.1 (14.6)

108.0 (17.9)/ 89.6 (17.3)

429/298

182/156

116/47

66/25

55/25

25/16

Systolic blood pressure (mmHg)

143.4 (20.0)

143.1 (20.2)

137.6 (20.5)

139.9 (18.2)

132.9 (23.7)

127.6 (22.7)

727

337

163

91

81

42

Diastolic blood pressure (mmHg)

84.2 (11.1)

84.1 (10.8)

81.0 (12.2)

82.1 (10.5)

81.3 (14.1)

80.2 (11.5)

727

338

163

91

81

42

Serum total cholesterol (mmol/l)

4.4 (1.1)

4.4 (0.9)

3.8 (0.9)

3.8 (1.0)

4.0 (1.2)

4.0 (1.4)

225

121

66

46

23

12

Serum HDL cholesterol (mmol/l)

1.2 (0.4)

1.3 (0.4)

1.4 (0.4)

1.3 (0.4)

1.1 (0.4)

1.3 (0.5)

219

119

65

45

23

11

Serum LDL cholesterol (mmol/l)

2.3 (0.8)

2.4 (0.8)

1.9 (0.6)

1.9 (0.7)

2.1 (0.9)

2.2 (0.9)

210

115

65

45

21

11

Lipid lowering medication (%)

24.7

20.3

60.5

55.7

38.0

22.2

190

73

104

54

35

10

Daily smokers (%)

12.7

11.0

11.9

10.1

12.7

12.2

88/691

36/327

19/160

9/89

10/79

5/41

Hb1Ac (%)

7.5 (1.1)

7.7 (1.7)

415

224

Oral antidiabetic drug and insulin (%)

12.3

13.1

95

47

Oral antidiabetic drug (%)

34.0

29.8

262

107

Insulin (%)

16.8

16.7

129

60

SCORE¹

8.0 (6.3)

7.6 (7.9)

215

115

NYHA²

2.4 (1.4)

2.5 (1.4)

52

30